Daraxonrasib Gains FDA Approval for Pancreatic Cancer

The U.S. FDA approved daraxonrasib for metastatic pancreatic ductal adenocarcinoma patients who have had prior therapy or are ineligible for multiagent systemic therapy, following trial results showing doubled overall and progression-free survival compared to chemotherapy.

This Wire brief sits within Fusion42's coverage of Biotech, and 21 sources have reported it.